These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 23727030)

  • 1. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.
    Yamada H; Suzuki K; Ichino N; Ando Y; Sawada A; Osakabe K; Sugimoto K; Ohashi K; Teradaira R; Inoue T; Hamajima N; Hashimoto S
    Clin Chim Acta; 2013 Sep; 424():99-103. PubMed ID: 23727030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.
    Salvoza NC; Klinzing DC; Gopez-Cervantes J; Baclig MO
    PLoS One; 2016; 11(4):e0153497. PubMed ID: 27077736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.
    Cermelli S; Ruggieri A; Marrero JA; Ioannou GN; Beretta L
    PLoS One; 2011; 6(8):e23937. PubMed ID: 21886843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease.
    Yamada H; Ohashi K; Suzuki K; Munetsuna E; Ando Y; Yamazaki M; Ishikawa H; Ichino N; Teradaira R; Hashimoto S
    Clin Chim Acta; 2015 Jun; 446():267-71. PubMed ID: 25958847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of circulating miR-20a, miR-27a, and miR-126 with non-alcoholic fatty liver disease in general population.
    Ando Y; Yamazaki M; Yamada H; Munetsuna E; Fujii R; Mizuno G; Ichino N; Osakabe K; Sugimoto K; Ishikawa H; Ohashi K; Teradaira R; Ohta Y; Hamajima N; Hashimoto S; Suzuki K
    Sci Rep; 2019 Dec; 9(1):18856. PubMed ID: 31827150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.
    Miyaaki H; Ichikawa T; Kamo Y; Taura N; Honda T; Shibata H; Milazzo M; Fornari F; Gramantieri L; Bolondi L; Nakao K
    Liver Int; 2014 Aug; 34(7):e302-7. PubMed ID: 24313922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease.
    Estep M; Armistead D; Hossain N; Elarainy H; Goodman Z; Baranova A; Chandhoke V; Younossi ZM
    Aliment Pharmacol Ther; 2010 Aug; 32(3):487-97. PubMed ID: 20497147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women.
    Liu PJ; Ma F; Lou HP; Zhu YN; Chen Y
    Climacteric; 2014 Dec; 17(6):692-9. PubMed ID: 24884478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver disease.
    Zhang Y; Cheng X; Lu Z; Wang J; Chen H; Fan W; Gao X; Lu D
    Diabetes Res Clin Pract; 2013 Mar; 99(3):327-34. PubMed ID: 23287814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease.
    Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Matono T; Kato J; Tokunaga S; Sugihara T; Hiramatsu A; Hyogo H; Tobita H; Sato S; Kawanaka M; Hara Y; Hino K; Chayama K; Murawaki Y; Isomoto H
    PLoS One; 2020; 15(2):e0219412. PubMed ID: 32106257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians--(CURES - 81).
    Gokulakrishnan K; Anjana RM; Indulekha K; Anuradha S; Mohan V
    Indian J Med Res; 2010 Sep; 132():271-7. PubMed ID: 20847373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.
    Latorre J; Moreno-Navarrete JM; Mercader JM; Sabater M; Rovira Ò; Gironès J; Ricart W; Fernández-Real JM; Ortega FJ
    Int J Obes (Lond); 2017 Apr; 41(4):620-630. PubMed ID: 28119530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.
    Tryndyak VP; Latendresse JR; Montgomery B; Ross SA; Beland FA; Rusyn I; Pogribny IP
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):52-9. PubMed ID: 22561871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
    Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
    Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
    Hochreuter MY; Dall M; Treebak JT; Barrès R
    Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
    Sun C; Huang F; Liu X; Xiao X; Yang M; Hu G; Liu H; Liao L
    Int J Mol Med; 2015 Mar; 35(3):847-53. PubMed ID: 25605429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated hepatic microRNAs underlie the association between non-alcoholic fatty liver disease and coronary artery disease.
    Braza-Boïls A; Marí-Alexandre J; Molina P; Arnau MA; Barceló-Molina M; Domingo D; Girbes J; Giner J; Martínez-Dolz L; Zorio E
    Liver Int; 2016 Aug; 36(8):1221-9. PubMed ID: 26901384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD).
    Jampoka K; Muangpaisarn P; Khongnomnan K; Treeprasertsuk S; Tangkijvanich P; Payungporn S
    Microrna; 2018; 7(3):215-222. PubMed ID: 29848284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.